PETALUMA, Calif.—RetinalGeniX Technologies Inc. has announced that it has contracted with MEDsan, Inc. to provide diagnostic testing services for its Institutional Review Board (IRB) to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration, which was previously announced on Oct. 30, 2023. Additionally, RetinalGeniX has started planning its pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration and Alzheimer’s/dementia complex studies as part of its DNA/RNA GPS initiative, according to the announcement.

RetinalGeniX has filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD. With its Pharmaco-Genetic Mapping, RetinalGeniX is developing a high-resolution retinal home and remote monitoring system that is intended to offer 24/7 real-time alerts to both physicians and patients and that does not require dilation of the pupil.

The technology is intended to prevent blindness through the early detection and treatment of ocular diseases and also to detect initial physiological changes that could indicate possible future systemic disease including neurodegenerative, cardiovascular, vascular, metabolic and diabetic conditions.

Jonathan Brenner, Ph.D., CEO of MEDsan, Inc., said, “We are pleased to extend our services into testing for wet macular degeneration, a field that we have been looking at for quite some time. We feel that RetinalGeniX is the right partner to start this venture with.”

Jerry Katzman, MD, chairman, president and CEO of RetinalGeniX said “MEDsan is a next-generation diagnostic CLIA-approved laboratory services facility equipped with the most technically advanced diagnostic equipment in the pharmaco-genetic space. Dr. Jonathan Brenner, Ph.D., and his team are specialists running diagnostic panels and dovetails RetinalGeniX’s clinical agenda to clinical study requirements. It's a perfect match. We look forward to working with MEDsan on this strategic venture.”